N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further update on its current
N4 Pharma PLC (N4P.L) Operations Update
N4 Pharma plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide an update on its current work
N4 Pharma PLC (N4P.L) Operations Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide an update on collaboration discussions and
Nigel Theobald, CEO of N4 Pharma PLC (N4P.L) Interview
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma PLC (N4P.L) Formulation Work Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide the following update on its ongoing
TPI provides its latest research note on N4 Pharma plc (N4P.L).
N4P has announced its appointment of Nanomerics Limited (‘Nanomerics’) to investigate the potential utility of Nuvec® in cancer therapy.
TPI provides its latest research note on N4 Pharma plc (N4P.L).
N4P has released an update on its ongoing work programmes.
N4 Pharma PLC (N4P.L) Operational Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide the following update on its ongoing
N4 Pharma PLC (N4PL) Covid-19 Proof of Concept Update
Covid-19 Proof of Concept Update and move to in vivo study
TPI provides its latest research note on N4 Pharma plc (N4P.L).
N4P has announced the appointment of Ardena Holding NV (‘Ardena’) as its contract development and manufacturing organisation (‘CDMO’) partner for the technology transfer and upscaling manufacture of Nuvec®, the Group’s unique silica nanoparticle
N4 Pharma PLC (N4P.L) Technology Transfer and Manufacturing Contract
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing, a novel delivery system for cancer treatments and vaccines, announces that it has appointed the API and Nanomedicines business unit